MGNX News and Press, MacroGenics Inc. From 07/30/20

MacroGenics (NASDAQ: MGNX ) : Q2 GAAP EPS of -$0.94 misses by $0.04 . More news on: MacroGenics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progr...

Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...

Rockville, MD, July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release...

The second half of the year could provide some solid wins for investors in the cancer therapeutics market. In recent years, Wall Street has flocked to many of these biotechnology companies because of their potential to deliver cutting-edge treatments and generate long-term returns. As cancer ...

Rockville, MD, July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Lancet Oncology has pu...

Shares of MacroGenics (NASDAQ: MGNX) soared over 156% in the first six months of the year, according to data provided by S&P Global Market Intelligence . For comparison, the S&P 500 limped through the first half of 2020 with a 4% decline.  The biopharma stock jumped after th...

"It is not in the stars to hold our destiny but in ourselves ." - William Shakespeare Today, we take look at an oncology name that had a volatile May as good news hit around its pipeline. Despite the overall recent rally in the stock, it looks like a decent covered call candidate given mu...

Rockville, MD, June 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American...

Rockville, MD, June 16, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Stephen Ec...